Stifel analyst Paul Matteis raised the firm’s price target on Dyne Therapeutics to $41 from $35 and keeps a Buy rating on the shares ahead of the company reporting additional data from both their DM1 and DMD studies in the second half of 2024. Dyne continues to dose escalate in both trials and now has cash through 2025 following their fundraising in January, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DYN:
- Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- Dyne Therapeutics initiated with a Buy at H.C. Wainwright
- Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
- Dyne Therapeutics to Present at February Investor Conferences
- Dyne Therapeutics resumes trading, up 29% after report of takeover interest